triazolam has been researched along with erythromycin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Antal, EJ; Phillips, JP; Smith, RB | 1 |
| Idänpään-Heikkilä, JJ; Mattila, MJ; Törnwall, M; Vanakoski, J | 1 |
| Mattila, MJ; Seppälä, T; Vanakoski, J | 1 |
| Kaneko, S; Kondo, T; Mihara, K; Morita, S; Otani, K; Tokinaga, N | 1 |
| Counihan, M; Duan, SX; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Shader, RI; von Moltke, LL; Wright, CE | 1 |
| Green, CE; Ito, K; Kanamitsu, S; Shimada, N; Sugiyama, Y; Tyson, CA | 1 |
| Ariyoshi, N; Igarashi, T; Ishii, I; Kitada, M; Nakamura, H; Nakasa, H; Ohmori, S | 1 |
1 review(s) available for triazolam and erythromycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for triazolam and erythromycin
| Article | Year |
|---|---|
A pharmacokinetic drug interaction between erythromycin and triazolam.
Topics: Adult; Drug Interactions; Erythromycin; Humans; Kinetics; Male; Triazolam | 1986 |
Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.
Topics: Administration, Oral; Adult; Brain; Capsules; Double-Blind Method; Drug Combinations; Drug Synergism; Erythromycin; Female; Humans; Male; Midazolam; Psychomotor Performance; Roxithromycin; Triazolam | 1993 |
Grapefruit juice does not enhance the effects of midazolam and triazolam in man.
Topics: Adult; Beverages; Citrus; Cross-Over Studies; Double-Blind Method; Erythromycin; Female; Food-Drug Interactions; Humans; Hypnotics and Sedatives; Male; Midazolam; Psychomotor Performance; Triazolam | 1996 |
Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Topics: Administration, Oral; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Azithromycin; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Erythromycin; Humans; Hypnotics and Sedatives; In Vitro Techniques; Microsomes, Liver; Oxidoreductases, N-Demethylating; Time Factors; Triazolam; Troleandomycin | 1998 |
10 other study(ies) available for triazolam and erythromycin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin.
Topics: Anti-Anxiety Agents; Drug Therapy, Combination; Erythromycin; Hallucinations; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nitrazepam; Pneumonia; Sleep Initiation and Maintenance Disorders; Triazolam | 1996 |
Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.
Topics: Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Humans; Microsomes, Liver; Mixed Function Oxygenases; Recombinant Proteins; Triazolam | 2000 |
Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes.
Topics: Adult; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Epoxy Compounds; Erythromycin; Humans; Hydroxylation; In Vitro Techniques; Isoxazoles; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Nevirapine; Pharmaceutical Preparations; Phenols; Steroids; Sulfonamides; Triazolam; Zonisamide | 2002 |